Company Overview and News


Add PIRS
to your dashboard

Headline News

Your Daily Pharma Scoop: Lipocine Ahead Of Ad Com, Ohr's MAKO Study Fails, Zafgen Provides Update

2018-01-06 seekingalpha
Today we will discuss Lipocine (LPCN), which fell more than 10% on Friday ahead of the Ad Com for its lead product candidate TLANDO, an oral testosterone replacement therapy (TRT). (243-7)

PIRS / Pieris Pharmaceuticals, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-01-05 fintel.io
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) has 67 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 20,885,967 shares. Largest shareholders include Orbimed Advisors Llc, Bvf Inc/il, Tekla Capital Management LLC, BlackRock Inc., Omega Fund Management, LLC, Sphera Funds Management Ltd., Schonfeld Strategic Advisors LLC, Lombard Odier Asset Management (USA) Corp, State Street Corp, and Millennium Management Llc. (84-0)

Pieris Pharmaceuticals (PIRS) Soars: Stock Adds 15.2% in Session

2017-12-27 zacks
Pieris Pharmaceuticals, Inc. (PIRS - Free Report) was a big mover last session, as the company saw its shares rise more than 15% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $5.64 to $6.37 in the past one-month time frame. (58-1)

4 Biotech Stocks That More Than Doubled This Year

2017-12-22 zacks
The biotech industry has been on the comeback trail in 2017 after facing a number of challenges last year including pricing pressure, rising competition, pipeline setbacks, pricing pressure, slowdown in growth of mature products and generic competition for certain key drugs. (146-1)

Zacks Value Investor Highlights: Diamondback Energy, KB Home, Pulte, Royal Caribbean and Macy's

2017-12-15 zacks
Chicago, IL – December 15, 2017 – Zacks Value Investor is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here: (https://www.zacks.com/stock/news/285871/how-to-use-a-basic-peg-screen-to-find-value-stocks) (154-0)

Urban Outfitters, Goodyear Tire & Rubber, 21st Century Fox, Walt Disney and Sky as Zacks Bull and Bear of the Day

2017-12-15 zacks
Chicago, IL – December 15, 2017 – Zacks Equity Research highlights Urban Outfitters Inc. (URBN - Free Report) as the Bull of the Day and The Goodyear Tire & Rubber Company (GT - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on 21st Century Fox (FOXA - Free Report) , Walt Disney Company (DIS - Free Report) and Sky plc (SKYAY - Free Report) . (150-0)

Zacks.com featured highlights: Incyte, AMC Entertainment, Mercadolibre, PTC and Clean Harbors

2017-12-15 zacks
Chicago, IL – December 15, 2017 - Stocks in this week’s article Incyte Corporation (INCY - Free Report) , AMC Entertainment Holdings, Inc. (AMC - Free Report) , Mercadolibre, Inc. (MELI - Free Report) , PTC Inc. (PTC - Free Report) and Clean Harbors, Inc. (CLH - Free Report) . (168-0)

Zacks.com featured highlights: Caterpillar, Oshkosh, Arista Networks, NVIDIA and H&E Equipment Services

2017-12-15 zacks
Chicago, IL – December 15, 2017 - Stocks in this week’s article Caterpillar Inc. (CAT - Free Report) , Oshkosh Corp (OSK - Free Report) , Arista Networks Inc. (ANET - Free Report) , NVIDIA Corp (NVDA - Free Report) and H&E Equipment Services Inc. (HEES - Free Report) . (255-0)

The Zacks Analyst Blog Highlights: BP, HollyFrontier, ConocoPhillips, Statoil and CNOOC

2017-12-15 zacks
Chicago, IL – December 15, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include BP plc (BP - Free Report) , HollyFrontier Corporation (HFC - Free Report) , ConocoPhillips (COP - Free Report) , Statoil ASA (STO - Free Report) and CNOOC Ltd. (144-0)

The Zacks Analyst Blog Highlights: Ford Motor, General Motors, Lear, Penske Automotive and Autoliv

2017-12-15 zacks
Chicago, IL – December 15, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Ford Motor Company (F - Free Report) , General Motors Company (GM - Free Report) , Lear Corp. (LEA - Free Report) , Penske Automotive Group, Inc. (150-0)

The Zacks Analyst Blog Highlights: Halozyme Therapeutics, Protagonist Therapeutics, Aptose Biosciences and Pieris Pharmaceuticals

2017-12-15 zacks
Chicago, IL – December 15, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Halozyme Therapeutics, Inc. (HALO - Free Report) , Protagonist Therapeutics, Inc. (PTGX - Free Report) , Aptose Biosciences Inc. (APTO - Free Report) and Pieris Pharmaceuticals, Inc. (168-0)

4 Top-Ranked Biotech Stocks Under $20 With Room for Growth

2017-12-14 zacks
The biotech industry witnessed a rebound in 2017 from last year’s challenges despite rising competition, pipeline setbacks, pricing pressure, slowdown in growth of mature products and generic competition for certain key drugs. (119-0)

BRIEF-Pieris Pharma Received Clearance to Initiate Its First-In-Human Study In Australia For PRS-060/AZD1402

2017-12-07 reuters
* PIERIS PHARMACEUTICALS - RECEIVED ETHICS AND REGULATORY CLEARANCE TO INITIATE ITS FIRST-IN-HUMAN STUDY IN AUSTRALIA FOR PRS-060/AZD1402 (41-0)

Pieris Pharmaceuticals Announces Ethics and Regulatory Clearance to Begin Clinical Testing of Inhaled Respiratory Program, PRS-060/AZD1402

2017-12-07 marketwired
BOSTON, MA--(Marketwired - December 07, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that it has received approval from the Human Research Ethics Committee and authority from the Therapeutic Goods Administration to initiate its first-in-human study in Australia for PRS-060/AZD1402, an inhaled Anticalin protein that targets IL-4Rα for the treatment of moderate to severe asthmatic patients that are not controlled on standard of care. (41-0)

BRIEF-Pieris Pharmaceuticals appoints James Geraghty as chairman of board of directors

2017-11-21 reuters
* Pieris Pharmaceuticals Inc - ‍Geraghty replaces Chau Khuong, who is stepping down from board​ Source text for Eikon: Further company coverage: (41-0)

Stock Research Report

Pieris Pharmaceuticals is a clinical-stage biopharmaceutical company that discovers and develops Anticalin® protein-based drugs to target validated disease pathways in a unique and transformative way. Pieris' pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Each of its development programs focus on the following:

  • 300-Series oncology drug candidates are multispecific Anticalin®-based proteins designed to engage immunomodulatory targets and consist of a variety of multifunctional biotherapeutics that genetically link antibody with one or more Anticalin proteins, thereby constituting...
Click for full article
CUSIP: 720795103